OVARIAN CANCER and US: media

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label media. Show all posts
Showing posts with label media. Show all posts

Monday, August 15, 2011

HealthNewsReview.org: Hot Chemotherapy Bath: Patients See Hope, Critics Hold Doubtsies | Holding Health and Medical Journalism Accountable



"Our Review Summary
This story opens readers' eyes to a debate that flared up before attendees of a recent meeting of the American Society of Clinical Oncology - but a debate that most of us wouldn't know about......"

Holding Health/Medical Journalism Accountable: Gene Therapy Cures Adult Leukemia



Note: some media reports reference 'possible' future role for ovarian cancer and therefore this link and again reminders of what is still in research/harms of hype.....

Gene Therapy Cures Adult Leukemia
August 10, 2011
Read The Story
RATING:
Somebody at WebMD must take responsibility for a headline that says "cure" after one year's experience in 3 patients. Cure used to be defined in 5 year terms. Is WebMD redefining the term?

Wednesday, March 09, 2011

NCI Cancer Bulletin Mar 2011: Ovarian Cancer Study Raises Questions about Developing Markers for Early Detection



 IMPORTANT/Blogger's Note:  longterm ovarian cancer survivours and caregivers will recall the historical 'hype' on new early detection tests - caution advised and confirming this as per the NCI Bulletin below (LPA would be one example only)


"During the last decade, Dr. Ransohoff noted, some researchers made strong claims about potential markers for ovarian cancer based on preliminary data. And though the markers did not pan out, these claims were repeated by members of the media, raising false hopes about early detection."



"A long-awaited assessment of potential biomarkers for detecting early ovarian cancer shows that blood levels of the CA-125 protein remain the best predictor of the disease. But if there is to be any hope that screening will reduce deaths from this disease, then more accurate markers would have to be developed, researchers concluded in the March Cancer Prevention Research.         (note: also see blog postings for related abstracts)

None of the 28 potential serum markers tested in the study outperformed CA-125. But for screening, the researchers noted, doctors would need a test that could detect a signal from tumors more than 6 months before diagnosis; CA-125 had its strongest signal within 6 months of diagnosis.

Although the results may seem disappointing, the findings can inform future efforts to detect the disease early, the study authors wrote. This idea was echoed by several biomarker experts who were not involved in the work but who stressed the importance of the findings......."cont'd

Tuesday, October 05, 2010

Audio/Video Insights, Implications, Questions, Answers: Report of the Investigators of Surgical and Pathology Issues at Three Essex County Hospitals



Note: this audio/video (62 minutes) refers to the investigation into this year's media reports concerning unnecessary mastectomies/pathology issues and national public exposure of the issue; quality of surgical and pathology care in Windsor/Essex counties (Ontario); notes co-operative investigation (patients??...still listening - terms of reference....)

Wednesday, June 16, 2010

A prime example of the problem with some TV physician-"journalists" - Gary Schwitzer's HealthNewsReview Blog (ASCO/ovarian cancer/Avastin) + my response



Note: my response:

"In our own ovarian cancer patient communities and over the long term, as survivours/family caregivers, many of us have learned to question media articles and abstracts. The SGO published a statement regarding the GOG 218 study shortly after the media events. 

In addition, on June 5th in Chicago on a separate ovarian cancer seminar the issue of the new finding of GOG 218 were discussed. The over-riding bottom line is that Avastin is not the panacea for all that ails ovarian cancer women and should be used very selectively. On which patients is of primary interest (obviously).

The issue at stake for ovarian cancer women is that no new treatments in the past 2 decades have shown any improvements over the standard and current first line therapy of Taxol and Carboplatin. 


No matter how bad it gets (QOL) and it does get very 'bad', ovarian cancer women want to live and will suffer much to do so. We need to understand this mindset while at the same time considering first most patient safety and always acknowledging the 'hype'. 


There is a duty for all those who care for ovarian cancer women to be informed.
Twitter, blogs, facebook and social media help also to educate patients on these issues - we hope."